AU5439790A - Cerebrovascular amyloid protein-specific monoclonal antibody sv17-6e10 - Google Patents

Cerebrovascular amyloid protein-specific monoclonal antibody sv17-6e10

Info

Publication number
AU5439790A
AU5439790A AU54397/90A AU5439790A AU5439790A AU 5439790 A AU5439790 A AU 5439790A AU 54397/90 A AU54397/90 A AU 54397/90A AU 5439790 A AU5439790 A AU 5439790A AU 5439790 A AU5439790 A AU 5439790A
Authority
AU
Australia
Prior art keywords
monoclonal antibody
specific monoclonal
amyloid protein
cerebrovascular amyloid
cerebrovascular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU54397/90A
Inventor
Cheng-Mo James Chen
Kwang S. Kim
Victor J. Sapienza
Guang Y. Wen
Henryk M. Wisniewski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation for Mental Hygiene Inc
Original Assignee
Research Foundation for Mental Hygiene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation for Mental Hygiene Inc filed Critical Research Foundation for Mental Hygiene Inc
Publication of AU5439790A publication Critical patent/AU5439790A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU54397/90A 1989-04-14 1990-04-13 Cerebrovascular amyloid protein-specific monoclonal antibody sv17-6e10 Abandoned AU5439790A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33898389A 1989-04-14 1989-04-14
US338983 1989-04-14

Publications (1)

Publication Number Publication Date
AU5439790A true AU5439790A (en) 1990-11-16

Family

ID=23326960

Family Applications (1)

Application Number Title Priority Date Filing Date
AU54397/90A Abandoned AU5439790A (en) 1989-04-14 1990-04-13 Cerebrovascular amyloid protein-specific monoclonal antibody sv17-6e10

Country Status (2)

Country Link
AU (1) AU5439790A (en)
WO (1) WO1990012871A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU687747B2 (en) * 1992-10-26 1998-03-05 Brigham And Women's Hospital Methods and compositions for the detection of soluble beta-amyloid peptide

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610493B1 (en) 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
US5837672A (en) 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
PT730643E (en) 1993-10-27 2001-06-29 Lilly Co Eli APP TRANSPORTATION ALGE TRANSGENIC ANIMALS WITH SWEDISH MUTACAO
US5744368A (en) * 1993-11-04 1998-04-28 Research Foundation Of State University Of New York Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR)
US6114133A (en) * 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US5863902A (en) * 1995-01-06 1999-01-26 Sibia Neurosciences, Inc. Methods of treating neurodegenerative disorders using protease inhibitors
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US6815175B2 (en) 2001-03-16 2004-11-09 Cornell Research Foundation, Inc. Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
PE20050627A1 (en) 2003-05-30 2005-08-10 Wyeth Corp HUMANIZED ANTIBODIES THAT RECOGNIZE THE BETA AMYLOID PEPTIDE
JP2008523815A (en) 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミテッド Humanized amyloid beta antibody for use in improving cognition
ES2259270B1 (en) 2005-03-09 2007-11-01 Consejo Superior De Investigaciones Cientificas IN VITRO DIAGNOSTIC METHOD OF ALZHEIMER'S DISEASE BY A MONOCLONAL ANTIBODY.
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
MX2009009234A (en) 2007-03-01 2009-12-01 Probiodrug Ag New use of glutaminyl cyclase inhibitors.
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
DK2182983T3 (en) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap TREATMENT OF AMYLOIDOGENIC DISEASES WITH HUMANIZED ANTI-ABETA ANTIBODIES
AU2008311367B2 (en) 2007-10-05 2014-11-13 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
US8445649B2 (en) 2007-10-29 2013-05-21 Tao Health Life Pharma Co., Ltd. Antibody and use thereof
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
KR101755737B1 (en) 2009-09-11 2017-07-07 프로비오드룩 아게 Heterocyclic derivatives as inhibitors of glutaminyl cyclase
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
CA2789440C (en) 2010-03-10 2020-03-24 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
JP5945532B2 (en) 2010-04-21 2016-07-05 プロビオドルグ エージー Benzimidazole derivatives as inhibitors of glutaminyl cyclase
CA2806909C (en) 2010-07-30 2019-12-17 Ac Immune S.A. Safe and functional humanized antibodies
ES2570167T3 (en) 2011-03-16 2016-05-17 Probiodrug Ag Benzimidazole derivatives as glutaminyl cyclase inhibitors
EP2511296A1 (en) 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antibody, kit and method for determination of amyloid peptides
ES2812698T3 (en) 2017-09-29 2021-03-18 Probiodrug Ag Glutaminyl cyclase inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU687747B2 (en) * 1992-10-26 1998-03-05 Brigham And Women's Hospital Methods and compositions for the detection of soluble beta-amyloid peptide

Also Published As

Publication number Publication date
WO1990012871A1 (en) 1990-11-01

Similar Documents

Publication Publication Date Title
AU5439790A (en) Cerebrovascular amyloid protein-specific monoclonal antibody sv17-6e10
AU5525090A (en) Monoclonal antibody to amyloid peptide
NZ236000A (en) Oligomeric monoclonal igg antibody composition
AU1964883A (en) Monoclonal antibody immunoassay
DK666389A (en) MONOCLONAL ANTIBODY
HUT74828A (en) Anti-alpha-v-integrin monoclonal antibody
DE68914244D1 (en) Monoclonal antibody.
EP0872558A4 (en) Monoclonal antibody recognizing serum amyloid a
EP0580859A4 (en) Anti-eda monoclonal antibody
IL90017A0 (en) Monoclonal antibodies
AU6031090A (en) Monoclonal antibodies against a tumor-associated antigen
IL92232A0 (en) Anti-fucosylceramide monoclonal antibody
AU6725190A (en) Anti-platelet monoclonal antibody
DK474189A (en) MONOCLONAL ANTIBODY
EP0431171A4 (en) Monoclonal antibody against c-reactive protein
GB8927389D0 (en) Monoclonal antibodies
NO890116D0 (en) MONOCLONAL ANTIBODIES.
DE69023717D1 (en) Monoclonal antibody.
DK413389A (en) MONOCLONAL ANTIBODIES
EP0265847A3 (en) Monoclonal antibody
IE893593L (en) Anti-fucosylcermiade monoclonal antibody
IE890064L (en) Monoclonal antibodies
IE891298L (en) Monoclonal antibodies
IE892557L (en) Monoclonal antibodies
GB9318912D0 (en) Humanised antibodies